BioCentury | Mar 13, 2019
Distillery Therapeutics

Inhibiting B3GALT5 or its biosynthetic products for breast and pancreatic cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting B3GALT5 or its downstream biosynthetic products SSEA-4 and globo-H could help treat breast and pancreatic cancers. In tissue...
BioCentury | Jul 21, 2017
Company News

OBI gains ThioBridge linker tech from Abzena for OBI-999 and other ADCs

Abzena plc (LSE:ABZA) granted OBI Pharma Inc. (TPEx:4174) exclusive, worldwide rights to ThioBridge antibody drug conjugate (ADC) linker- technology which OBI will use to develop its preclinical cancer candidate OBI-999 and other undisclosed ADCs to...
BioCentury | Aug 25, 2016
Distillery Techniques

Techniques: Immune cell profiling of melanoma biopsies to predict responses to anti-PD-1 mAbs

Biomarkers TECHNOLOGY: Tissue markers Immune cell profiling of melanoma biopsies could help predict patient responses to anti- PD-1 mAbs. In a longitudinal study of 46 patients treated with the anti- PD-1 mAb Keytruda pembrolizumab after...
BioCentury | Jul 14, 2016
Distillery Therapeutics

Therapeutics: Angiotensin II type 1 receptor (AGTR1)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest AGTR1 inhibitors could help sensitize obese pancreatic ductal adenocarcinoma (PDAC) patients to chemotherapy. In PDAC patients who underwent surgical tumor resection, adjuvant chemotherapy increased survival...
BioCentury | Apr 28, 2016
Distillery Therapeutics

Therapeutics: Stage-specific embryonic antigen-4 (SSEA-4); integrin β4

Ophthalmic disease INDICATION: Blindness; corneal transplant Cell culture and rabbit studies suggest corneal sheets derived from human induced pluripotent stem (iPS) cells could help treat corneal blindness. Human iPS cells were differentiated into a tissue...
BioCentury | Apr 14, 2016
Distillery Techniques

Techniques: Plasma detection of receptor tyrosine kinase (RTK) ectodomains to predict response to kinase inhibitors

Biomarkers TECHNOLOGY: Plasma markers Plasma levels of soluble RTK extracellular domains could help predict response to inhibitors of MEK , BRAF and other kinases. In 11 melanoma patients treated with the MEK inhibitor Mekinist trametinib plus...
BioCentury | Apr 7, 2016
Distillery Therapeutics

Therapeutics: K-Ras (KRAS)

Cancer INDICATION: Lung cancer Cell culture studies identified a covalent inhibitor of GDP-bound mutant KRAS that could help treat lung cancer. Screening of a library of covalent electrophilic compounds in a human non-small cell lung...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: E1A binding protein p300 (EP300; p300); CREB binding protein (CREBBP; CBP)

Cancer INDICATION: Cancer; leukemia Cell culture and mouse studies suggest inhibiting EP300 could help treat CREBBP-deficient cancers. In a human CREBBP-deficient lung cancer cell line, siRNA targeting EP300 decreased viability and proliferation and increased apoptosis...
BioCentury | Jan 21, 2016
Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); chemokine CXC motif ligand 5 (CXCL5; ENA78)

Cancer INDICATION: Prostate cancer Mouse and cell culture studies suggest CXCR2 inhibitors could help treat invasive prostate cancer. In a mouse model of highly invasive prostate cancer, tumor levels of CXCL5 and CXCR2-expressing myeloid-derived suppressor...
BioCentury | Aug 20, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-196a (miR-196a); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc); homeobox B7 (HOXB7)

Cancer INDICATION: Breast cancer Studies in patient samples, cell culture and mice suggest miR-196a or inhibition of MYC could help treat tamoxifen-resistant breast cancer. In tumors from estrogen receptor-positive breast cancer patients previously treated with...
Items per page:
1 - 10 of 27